Medsafe approves Perjeta and Kadcyla for HER2+ metastatic breast cancer treatment
Medsafe, the Government organisation responsible for regulation of medicines in NZ, has approved two new drugs, Perjeta and Kadcyla, for treatment of HER2+ metastatic breast cancer.
Both drugs are made by Roche, which developed Herceptin. Perjeta (pertuzumab) is used in conjunction with Herceptin and docetaxel (chemotherapy). Kadcyla (referred to in studies as T-DM1) is used for patients with advanced or metastatic breast cancer, who may previously have used Herceptin.
Both drugs have impressive research studies – CLEOPATRA and EMILIA – showing significant improvements in progression free survival.
Note, neither drug has been approved by Pharmac for prescription in the public health system. New Zealand women interested in obtaining these drugs will at this stage need to discuss private treatment with their oncologist.